Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Operating Expenses (2020 - 2025)

Mirum Pharmaceuticals has reported Operating Expenses over the past 6 years, most recently at $153.5 million for Q4 2025.

  • Quarterly results put Operating Expenses at $153.5 million for Q4 2025, up 24.15% from a year ago — trailing twelve months through Dec 2025 was $543.4 million (up 28.02% YoY), and the annual figure for FY2025 was $543.4 million, up 28.02%.
  • Operating Expenses for Q4 2025 was $153.5 million at Mirum Pharmaceuticals, up from $130.4 million in the prior quarter.
  • Over the last five years, Operating Expenses for MIRM hit a ceiling of $153.5 million in Q4 2025 and a floor of $45.6 million in Q1 2022.
  • Median Operating Expenses over the past 5 years was $67.5 million (2022), compared with a mean of $83.2 million.
  • Biggest five-year swings in Operating Expenses: surged 120.22% in 2021 and later dropped 4.17% in 2022.
  • Mirum Pharmaceuticals' Operating Expenses stood at $48.7 million in 2021, then grew by 27.41% to $62.1 million in 2022, then surged by 64.56% to $102.1 million in 2023, then grew by 21.05% to $123.6 million in 2024, then increased by 24.15% to $153.5 million in 2025.
  • The last three reported values for Operating Expenses were $153.5 million (Q4 2025), $130.4 million (Q3 2025), and $132.8 million (Q2 2025) per Business Quant data.